Please assess the completion status of the following clinical trial:

Trial Title: Multihance at 3 Tesla (3T) in Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Was 18 years or older~* Provided written informed consent~* Scheduled for MRI~* Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days~Exclusion Criteria:~* Pregnant or lactating females~* Allergy to one or more of the ingredients in the products or hypersensitivity to any metals~* Congestive heart failure, class IV~* Previous stroke in the past year~* Received another contrast agent within 24 hours pre and post each exam~* Investigational product~* Contraindications to MRI~* Severe claustrophobia~* Surgery with 3 weeks prior~* Steroid therapy or radiosurgery between two exams

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MultiHance (Type: ACTIVE_COMPARATOR): 0.5 M MultiHance at a single injection
- Magnevist (Type: ACTIVE_COMPARATOR): 0.5 M Magnevist at a single injection

Based on this trial design, predict the completion outcome and termination type (if applicable).